- Price
- $12.47
- Day
- +4.18%
- Mkt Cap
- $833.38M
- 52W Range
- $4.97 – $20.88
- Volume
- 1.46M
- Beta
- 1.01
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
BOSTON, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Rapid7, Inc. (“Rapid7”) (NASDAQ: RPD), a global leader in AI-powered managed cybersecurity operations, announced that the company granted inducement awards, effective as of September 15, 2026, to employees as a material inducement to commence employment with Rapid7 and its subsidiaries.
Read full article
Markets are rattled ahead of Wednesday's Fed decision, and Wall Street analysts are making bold moves on names like Eli Lilly, Etsy, Northrop Grumman, and Rivian. Find out which stocks got upgraded, downgraded, or newly covered before the opening bell.
Read full article
Hsbc Holdings PLC boosted its position in Rapid7, Inc. (NASDAQ: RPD) by 252.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 120,946 shares of the technology company's stock after purchasing an additional 86,623 shares during the period.
Read full article
Rapid7, Inc. (RPD) Presents at Citi's 2026 Global TMT Conference Transcript
Read full article
Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV) Quoin Expects to Initiate Phase 2 Study in 2H 2026; Study Plans to Enroll up to 12 Pediatric and Adult Peeling Skin Patients in the U.S. and Europe There are Currently No Approved Treatments for Peeling Skin Syndrome ASHBURN, Va., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
Read full article
Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV) Quoin Expects to Initiate Phase 2 Study in 2H 2026; Study Plans to Enroll up to 12 Pediatric and Adult Peeling Skin Patients in the U.S. and Europe There are Currently No Approved Treatments for Peeling Skin Syndrome ASHBURN, Va., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
Read full article
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a global leader in AI-powered managed cybersecurity operations, today announced that the company will be attending the following conferences:
Read full article
On September 02, 2026, Rapid7 Inc (RPD) shares fell 7.8% to $11.07, marking a significant decline in an already challenging year. The stock has fluctuated betwe
Read full article